Search

Your search keyword '"Jørgensen, Kristin K"' showing total 23 results
Start Over Author "Jørgensen, Kristin K"
23 results on '"Jørgensen, Kristin K"'

1. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Author

Jyssum, Ingrid, Kared, Hassen, Tran, Trung T, Tveter, Anne T, Provan, Sella A, Sexton, Joseph, Jørgensen, Kristin K, Jahnsen, Jørgen, Kro, Grete B, Warren, David J, Vaage, Eline B, Kvien, Tore K, Nissen-Meyer, Lise-Sofie H, Anderson, Ane Marie, Grødeland, Gunnveig, Haavardsholm, Espen A, Vaage, John Torgils, Mjaaland, Siri, Syversen, Silje Watterdal, Lund-Johansen, Fridtjof, Munthe, Ludvig A, and Goll, Guro Løvik

Published
2022
Full Text
View/download PDF

2. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Author

Hedin, Charlotte Rose Hawkey, Sado, Gina, Ndegwa, Nelson, Lytvyak, Ellina, Mason, Andrew, Montano-Loza, Aldo, Gerussi, Alessio, Saffioti, Francesca, Thorburn, Douglas, Nilsson, Emma, Larsson, Geir, Moum, Bjørn A., van Munster, Kim N., Ponsioen, Cyriel Y., Levy, Cynthia, Nogueira, Nicholas F., Bowlus, Christopher L., Gotlieb, Neta, Shibolet, Oren, Lynch, Kate D., Chapman, Roger W., Rupp, Christian, Vesterhus, Mette, Jørgensen, Kristin K., Rorsman, Fredrik, Schramm, Christoph, Sabino, João, Vermeire, Severine, Zago, Alessandra, Cazzagon, Nora, Marschall, Hanns-Ulrich, Ytting, Henriette, Ben Belkacem, Karima, Chazouilleres, Olivier, Almer, Sven, and Bergquist, Annika

Published
2020
Full Text
View/download PDF

3. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials

Author

Jørgensen, Kristin K., Goll, Guro L., Sexton, Joe, Bolstad, Nils, Olsen, Inge C., Asak, Øivind, Berset, Ingrid P., Blomgren, Ingrid M., Dvergsnes, Katrine, Florholmen, Jon, Frigstad, Svein O., Henriksen, Magne, Hagfors, Jon, Huppertz-Hauss, Gert, Haavardsholm, Espen A., Klaasen, Rolf A., Moum, Bjørn, Noraberg, Geir, Prestegård, Ulf, Rydning, Jan H., Sagatun, Liv, Seeberg, Kathrine A., Torp, Roald, Vold, Cecilia, Warren, David J., Ystrøm, Carl M., Lundin, Knut E. A., Kvien, Tore, and Jahnsen, Jørgen

Published
2020
Full Text
View/download PDF

4. Cholestatic liver disease is alleviated by colitis-induced inhibition of bile acid synthesis

Author

Gui, Wenfang, primary, Hole, Mikal Jacob, additional, Molinaro, Antonio, additional, Edlund, Karolina, additional, Jørgensen, Kristin K., additional, Su, Huan, additional, Begher-Tibbe, Brigitte, additional, Gaßler, Nikolaus, additional, Schneider, Carolin V., additional, Muthukumarasamy, Uthayakumar, additional, Mohs, Antje, additional, Liao, Lijun, additional, Jäger, Julius, additional, Mertens, Christian, additional, Bergheim, Ina, additional, Strowig, Till, additional, Hengstler, Jan G., additional, Hov, Johannes R., additional, Marschall, Hanns-Ulrich, additional, Trautwein, Christian, additional, and Schneider, Kai Markus, additional

Published
2023
Full Text
View/download PDF

5. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Author

Berset, Ingrid P, Fevang, Bjørg TS, Florholmen, Jon, Kalstad, Synøve, Mørk, Nils J, Ryggen, Kristin, Tveit, Kåre S, Sæther, Sigrun K, Gulbrandsen, Bjørn, Hagfors, Jon, Waksvik, Kenneth, Warren, David, Henanger, Karoline J., Asak, Øivind, Baigh, Somyeh, Blomgren, Ingrid M, Bruun, Trude J, Dvergsnes, Katrine, Frigstad, Svein O, Gjesdal, Clara G, Grandaunet, Berit H J, Hansen, Inger M, Hatten, Ingvild S H, Huppertz-Hauss, Gert, Henriksen, Magne, Hoie, Sunniva S, Krogh, Jan, Kruse, Julia R, Ljoså, Maud-Kristine A, Midtgard, Irina P, Mielnik, Pawel, Moum, Bjørn, Noraberg, Geir, Poyan, Armin, Prestegård, Ulf, Rashid, Haroon U, Rydning, Jan Henrik, Sagatun, Liv, Seeberg, Kathrine A, Skjetne, Kristine, Strand, Eldri K, Stray, Hilde, Stray, Njaal, Torp, Roald, Vold, Cecilia, Ystrøm, Carl M, Zettel, Camilla C, Jørgensen, Kristin K, Olsen, Inge C, Goll, Guro L, Lorentzen, Merete, Bolstad, Nils, Haavardsholm, Espen A, Lundin, Knut E A, Mørk, Cato, Jahnsen, Jørgen, and Kvien, Tore K

Published
2017
Full Text
View/download PDF

7. No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis

Author

Zenouzi, Roman, Weismüller, Tobias J., Jørgensen, Kristin K., Bubenheim, Michael, Lenzen, Henrike, Hübener, Peter, Schulze, Kornelius, Weiler-Normann, Christina, Sebode, Marcial, Ehlken, Hanno, Pannicke, Nadine, Hartl, Johannes, Peiseler, Moritz, Hübener, Sina, Karlsen, Tom H., Boberg, Kirsten M., Manns, Michael P., Lohse, Ansgar W., and Schramm, Christoph

Published
2016
Full Text
View/download PDF

8. Therapeutic drug monitoring in inflammatory bowel disease:implementation, utilization, and barriers in clinical practice in Scandinavia

Author

Bjørlykke, Kristin H., Jahnsen, Jørgen, Brynskov, Jørn, Molander, Pauliina, Eberhardson, Michael, Davidsdottir, Loà G., Sipponen, Taina, Hjortswang, Henrik, Goll, Guro Løvik, Syversen, Silje Watterdal, Langholz, Ebbe, Jørgensen, Kristin K., Steenholdt, Casper, Bjørlykke, Kristin H., Jahnsen, Jørgen, Brynskov, Jørn, Molander, Pauliina, Eberhardson, Michael, Davidsdottir, Loà G., Sipponen, Taina, Hjortswang, Henrik, Goll, Guro Løvik, Syversen, Silje Watterdal, Langholz, Ebbe, Jørgensen, Kristin K., and Steenholdt, Casper

Abstract

Background and aims: Therapeutic drug monitoring (TDM) may optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). The study aimed to investigate implementation and utilization of TDM in Scandinavia. Methods: A web-based questionnaire on the use of TDM was distributed to Scandinavian gastroenterologists via the national societies. Results: In total, 297 IBD physicians prescribing biologic therapies, equally distributed between community and university hospitals, were included (response rate 42%) (Norway 118 (40%), Denmark 86 (29%), Sweden 50 (17%), Finland 33 (11%), Iceland 10 (3%)). Overall, TDM was applied during biologic therapies by 87%, and for TNF-inhibitors >90%. Among the users, reactive and proactive TDM were utilized by 90% and 63%, respectively. Danish physicians were significantly less inclined to use TDM compared to other Scandinavian countries; (58% vs 98%); OR 0.03 [0.01–0.09], p < 0.001). Reactive TDM was commonly applied at primary (74%) and secondary (99%) treatment failure. Proactive TDM was used by 80% during maintenance therapy and 56% during induction and more commonly utilized in Norway (p < 0.001), and by physicians managing >10 IBD patients/week (p = 0.005). TDM scenarios were interpreted in accord with available evidence but with discrepancies for proactive TDM. The main barriers to TDM were lack of guidelines (51%) and time lag between sampling and results (49%). TDM of thiopurines was routinely used by 87%. Conclusion: TDM of biologic and thiopurine therapies has been broadly implemented into clinical practice in Scandinavia. However, physicians call for TDM guidelines detailing indications and interpretations of test results along with improved test response times.

Published
2023

9. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis

Author

Gui, Wenfang, Hole, Mikal Jacob, Molinaro, Antonio, Edlund, Karolina, Jørgensen, Kristin K., Su, Huan, Begher-Tibbe, Brigitte, Gaßler, Nikolaus, Schneider, Carolin Victoria, Muthukumarasamy, Uthayakumar, Mohs, Antje, Liao, Lijun, Jaeger, Julius, Mertens, Christian J., Bergheim, Ina, Strowig, Till, Hengstler, Jan G., Hov, Johannes R., Marschall, Hanns-Ulrich, Trautwein, Christian, and Schneider, Kai Markus

Subjects
ddc:500
Abstract

Nature Communications 14, 3304 (2023). doi:10.1038/s41467-023-38840-8, Published by Nature Publishing Group UK, [London]

Published
2023
Full Text
View/download PDF

10. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Author

Bjørlykke, Kristin H., primary, Jahnsen, Jørgen, additional, Brynskov, Jørn, additional, Molander, Pauliina, additional, Eberhardson, Michael, additional, Davidsdottir, Loà G., additional, Sipponen, Taina, additional, Hjortswang, Henrik, additional, Goll, Guro Løvik, additional, Syversen, Silje Watterdal, additional, Langholz, Ebbe, additional, Jørgensen, Kristin K., additional, and Steenholdt, Casper, additional

Published
2022
Full Text
View/download PDF

11. Immunogenicity and Safety of Standard and Third‐Dose SARS – CoV ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy

Author

Syversen, Silje W., primary, Jyssum, Ingrid, additional, Tveter, Anne T., additional, Tran, Trung T., additional, Sexton, Joseph, additional, Provan, Sella A., additional, Mjaaland, Siri, additional, Warren, David J., additional, Kvien, Tore K., additional, Grødeland, Gunnveig, additional, Nissen‐Meyer, Lise S. H., additional, Ricanek, Petr, additional, Chopra, Adity, additional, Andersson, Ane M., additional, Kro, Grete B., additional, Jahnsen, Jørgen, additional, Munthe, Ludvig A., additional, Haavardsholm, Espen A., additional, Vaage, John T., additional, Lund‐Johansen, Fridtjof, additional, Jørgensen, Kristin K., additional, and Goll, Guro L., additional

Published
2022
Full Text
View/download PDF

12. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.

Author

Bjørlykke, Kristin H., Jahnsen, Jørgen, Brynskov, Jørn, Molander, Pauliina, Eberhardson, Michael, Davidsdottir, Loà G., Sipponen, Taina, Hjortswang, Henrik, Goll, Guro Løvik, Syversen, Silje Watterdal, Langholz, Ebbe, Jørgensen, Kristin K., and Steenholdt, Casper

Subjects
DRUG monitoring, INFLAMMATORY bowel diseases, BIOTHERAPY, PHYSICIANS, COMMUNITIES
Abstract

Therapeutic drug monitoring (TDM) may optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). The study aimed to investigate implementation and utilization of TDM in Scandinavia. A web-based questionnaire on the use of TDM was distributed to Scandinavian gastroenterologists via the national societies. In total, 297 IBD physicians prescribing biologic therapies, equally distributed between community and university hospitals, were included (response rate 42%) (Norway 118 (40%), Denmark 86 (29%), Sweden 50 (17%), Finland 33 (11%), Iceland 10 (3%)). Overall, TDM was applied during biologic therapies by 87%, and for TNF-inhibitors >90%. Among the users, reactive and proactive TDM were utilized by 90% and 63%, respectively. Danish physicians were significantly less inclined to use TDM compared to other Scandinavian countries; (58% vs 98%); OR 0.03 [0.01–0.09], p < 0.001). Reactive TDM was commonly applied at primary (74%) and secondary (99%) treatment failure. Proactive TDM was used by 80% during maintenance therapy and 56% during induction and more commonly utilized in Norway (p < 0.001), and by physicians managing >10 IBD patients/week (p = 0.005). TDM scenarios were interpreted in accord with available evidence but with discrepancies for proactive TDM. The main barriers to TDM were lack of guidelines (51%) and time lag between sampling and results (49%). TDM of thiopurines was routinely used by 87%. TDM of biologic and thiopurine therapies has been broadly implemented into clinical practice in Scandinavia. However, physicians call for TDM guidelines detailing indications and interpretations of test results along with improved test response times. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. FRI-334 - Cholestatic liver disease is alleviated by colitis-induced inhibition of bile acid synthesis

Author

Gui, Wenfang, Hole, Mikal Jacob, Molinaro, Antonio, Edlund, Karolina, Jørgensen, Kristin K., Su, Huan, Begher-Tibbe, Brigitte, Gaßler, Nikolaus, Schneider, Carolin V., Muthukumarasamy, Uthayakumar, Mohs, Antje, Liao, Lijun, Jäger, Julius, Mertens, Christian, Bergheim, Ina, Strowig, Till, Hengstler, Jan G., Hov, Johannes R., Marschall, Hanns-Ulrich, Trautwein, Christian, and Schneider, Kai Markus

Published
2023
Full Text
View/download PDF

19. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Author

Jørgensen, Kristin K, primary, Olsen, Inge C, additional, Goll, Guro L, additional, Lorentzen, Merete, additional, Bolstad, Nils, additional, Haavardsholm, Espen A, additional, Lundin, Knut E A, additional, Mørk, Cato, additional, Jahnsen, Jørgen, additional, Kvien, Tore K, additional, Berset, Ingrid P, additional, Fevang, Bjørg TS, additional, Florholmen, Jon, additional, Kalstad, Synøve, additional, Mørk, Nils J, additional, Ryggen, Kristin, additional, Tveit, Kåre S, additional, Sæther, Sigrun K, additional, Gulbrandsen, Bjørn, additional, Hagfors, Jon, additional, Waksvik, Kenneth, additional, Warren, David, additional, Henanger, Karoline J., additional, Asak, Øivind, additional, Baigh, Somyeh, additional, Blomgren, Ingrid M, additional, Bruun, Trude J, additional, Dvergsnes, Katrine, additional, Frigstad, Svein O, additional, Gjesdal, Clara G, additional, Grandaunet, Berit H J, additional, Hansen, Inger M, additional, Hatten, Ingvild S H, additional, Huppertz-Hauss, Gert, additional, Henriksen, Magne, additional, Hoie, Sunniva S, additional, Krogh, Jan, additional, Kruse, Julia R, additional, Ljoså, Maud-Kristine A, additional, Midtgard, Irina P, additional, Mielnik, Pawel, additional, Moum, Bjørn, additional, Noraberg, Geir, additional, Poyan, Armin, additional, Prestegård, Ulf, additional, Rashid, Haroon U, additional, Rydning, Jan Henrik, additional, Sagatun, Liv, additional, Seeberg, Kathrine A, additional, Skjetne, Kristine, additional, Strand, Eldri K, additional, Stray, Hilde, additional, Stray, Njaal, additional, Torp, Roald, additional, Vold, Cecilia, additional, Ystrøm, Carl M, additional, and Zettel, Camilla C, additional

Published
2017
Full Text
View/download PDF

20. A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency

Author

Jørgensen, Silje F, primary, Reims, Henrik M, additional, Frydenlund, Didrik, additional, Holm, Kristian, additional, Paulsen, Vemund, additional, Michelsen, Annika E, additional, Jørgensen, Kristin K, additional, Osnes, Liv T, additional, Bratlie, Jorunn, additional, Eide, Tor J, additional, Dahl, Christen P, additional, Holter, Ellen, additional, Tronstad, Rune R, additional, Hanevik, Kurt, additional, Brattbakk, Hans-Richard, additional, Kaveh, Fatemeh, additional, Fiskerstrand, Torunn, additional, Kran, Anne-Marte B, additional, Ueland, Thor, additional, Karlsen, Tom H, additional, Aukrust, Pål, additional, Lundin, Knut E A, additional, and Fevang, Børre, additional

Published
2016
Full Text
View/download PDF

23. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis.

Author

Gui W, Hole MJ, Molinaro A, Edlund K, Jørgensen KK, Su H, Begher-Tibbe B, Gaßler N, Schneider CV, Muthukumarasamy U, Mohs A, Liao L, Jaeger J, Mertens CJ, Bergheim I, Strowig T, Hengstler JG, Hov JR, Marschall HU, Trautwein C, and Schneider KM

Subjects
Animals, Mice, Inflammation complications, Bile Acids and Salts, Cholangitis, Sclerosing complications, Cholangitis, Sclerosing therapy, Inflammatory Bowel Diseases complications, Cholestasis complications, Colitis complications, Liver Diseases
Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of the biliary tree. The majority of PSC patients suffer from concomitant inflammatory bowel disease (IBD), which has been suggested to promote disease development and progression. However, the molecular mechanisms by which intestinal inflammation may aggravate cholestatic liver disease remain incompletely understood. Here, we employ an IBD-PSC mouse model to investigate the impact of colitis on bile acid metabolism and cholestatic liver injury. Unexpectedly, intestinal inflammation and barrier impairment improve acute cholestatic liver injury and result in reduced liver fibrosis in a chronic colitis model. This phenotype is independent of colitis-induced alterations of microbial bile acid metabolism but mediated via hepatocellular NF-κB activation by lipopolysaccharide (LPS), which suppresses bile acid metabolism in-vitro and in-vivo. This study identifies a colitis-triggered protective circuit suppressing cholestatic liver disease and encourages multi-organ treatment strategies for PSC., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results